The distinguishing features of human metapneumovirus and respiratory syncytial virus

Reviews in Medical Virology

Volumn 20, Issue 4, 2010, Pages 245-260

  Papenburg, Jesse ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NUCLEOSIDE ANALOG; PALIVIZUMAB; RIBAVIRIN; VIRUS VACCINE;

ACTIVE IMMUNIZATION; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ASTHMA; CLINICAL FEATURE; DISEASE SEVERITY; DRUG COST; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTION RISK; LABORATORY DIAGNOSIS; LOWER RESPIRATORY TRACT INFECTION; METAPNEUMOVIRUS INFECTION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PREVALENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEASONAL VARIATION; SEROEPIDEMIOLOGY; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS GENOME; VIRUS TRANSMISSION; WHEEZING; CLASSIFICATION; COMPARATIVE STUDY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METAPNEUMOVIRUS; PARAMYXOVIRUS INFECTION; PATHOGENICITY;

HUMANS; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 77954153198     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.651     Document Type: Review

References (150)

1. Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002; 112(Suppl 6A): 4S-12S.
2. Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: data, methods, and results for 2001. In Global Burden of Disease and Risk Factors, Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL (eds). Oxford University Press and the World Bank: New York, 2006; 45-93.
3. Robinson CC. Respiratory viruses. In Clinical Virology Manual, Steven S, Hodinka RL, Young Stephen A, Wiedbrauk Danny (eds). ASM Press: Washington, DC, 2009; 203-248.
4. Raymond F, Carbonneau J, Boucher N, et al. Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. J Clin Microbiol 2009; 47(3): 743-750.
5. Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21(4): 716-747.
6. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956; 92(3): 544-549.
7. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282(15): 1440-1446.
8. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113(6): 1758-1764.
9. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360(6): 588-598.
10. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001; 33(6): 792-796.
11. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7(6): 719-724.
12. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2006; 19(3): 546-557.
13. International Committee on Taxonomy of Viruses: ICTVdb Index of Viruses. http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/index.htm. [15 November 2009].
14. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295(1): 119-132.
15. de Graaf M, Osterhaus AD, Fouchier RA, Holmes EC. Evolutionary dynamics of human and avian metapneumoviruses. J Gen Virol 2008; 89(Pt 12): 2933-2942.
16. Peret TC, Boivin G, Li Y, et al. Characterization of humanmetapneumoviruses isolated from patients in North America. J Infect Dis 2002; 185(11): 1660-1663.
17. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 2004; 78(8): 4363-4369.
18. Biacchesi S, Skiadopoulos MH, Boivin G, et al. Genetic diversity between human metapneumovirus subgroups. Virology 2003; 315(1): 1-9.
19. Yang CF, Wang CK, Tollefson SJ, et al. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Virol J 2009; 6(1): 138.
20. de Graaf M, Schrauwen EJ, Herfst S, van Amerongen G, Osterhaus AD, Fouchier RA. Fusion protein is the main determinant of metapneumovirus host tropism. J Gen Virol 2009; 90(Pt 6): 1408-1416.
21. Schowalter RM, Chang A, Robach JG, Buchholz UJ, Dutch RE. Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry. J Virol 2009; 83(3): 1511-1522.
22. Peret TC, Abed Y, Anderson LJ, Erdman DD, Boivin G. Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. J Gen Virol 2004; 85(Pt 3): 679-686.
23. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000; 13(1): 1-15.
24. Bastien N, Liu L, Ward D, Taylor T, Li Y. Genetic variability of the G glycoprotein gene of human metapneumovirus. J Clin Microbiol 2004; 42(8): 3532-3537.
25. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001; 289(2): 283-296.
26. Biacchesi S, Skiadopoulos MH, Yang L, et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 2004; 78(23): 12877-12887.
27. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006; 345(2): 492-501.
28. Herfst S, Fouchier RA. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 2008; 41(1): 49-52.
29. Mufson MA, Belshe RB, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered fromchildrenwith two consecutive infections. J Clin Microbiol 1987; 25(8): 1535-1539.
30. Pavlin JA, Hickey AC, Ulbrandt N, et al. Human metapneumovirus reinfection among children in Thailand determined by ELISA using purified soluble fusion protein. J Infect Dis 2008; 198(6): 836-842.
31. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350(5): 443-450.
32. Lopez JA, Andreu D, Carreno C, Whyte P, Taylor G, Melero JA. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J Gen Virol 1993; 74(Pt 12): 2567-2577.
33. Boivin G, Mackay I, Sloots TP, et al. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis 2004; 10(6): 1154-1157.
34. Mackay IM, Bialasiewicz S, Waliuzzaman Z, et al. Use of the P gene to genotype human metapneumovirus identifies 4 viral subtypes. J Infect Dis 2004; 190(11): 1913-1918.
35. van den Hoogen BG, Herfst S, Sprong L, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004; 10(4): 658-666.
36. Huck B, Scharf G, Neumann-Haefelin D, Puppe W, Weigl J, Falcone V. Novel human metapneumovirus sublineage. Emerg Infect Dis 2006; 12(1): 147-150.
37. Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186(9): 1330-1334.
38. Wertz GW, Moudy RM. Antigenic and genetic variation in human respiratory syncytial virus. Pediatr Infect Dis J 2004; 23(1 Suppl): S19-24.
39. Endo R, Ebihara T, Ishiguro N, et al. Detection of four genetic subgroup-specific antibodies to human metapneumovirus attachment (G) protein in human serum. J Gen Virol 2008; 89(Pt 8): 1970-1977.
40. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004; 78(13): 6927-6937.
41. Acute respiratory infections (update September 2009): respiratory syncytial virus and parainfluenza viruses. http://www.who.int/vaccine-research/ diseases/ari/en/index2.html. [15 November 2009].
42. Chano F, Rousseau C, Laferriere C, Couillard M, Charest H. Epidemiological survey of human metapneumovirus infection in a large pediatric tertiary care center. J Clin Microbiol 2005; 43(11): 5520-5525.
43. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J 2007; 26(11 Suppl): S41-S45.
44. Oliveira DB, Durigon EL, Carvalho AC, et al. Epidemiology and genetic variability of human metapneumovirus during a 4-year-long study in Southeastern Brazil. J Med Virol 2009; 81(5): 915-921.
45. Welliver R. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Paediatr Respir Rev 2009; 10 (Suppl 1): 6-8.
46. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes EA. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009; 154(2): 296-298.
47. Peret TC, Hall CB, Hammond GW, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis 2000; 181(6): 1891-1896.
48. Williams JV, Wang CK, Yang CF, et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 2006; 193(3): 387-395.
49. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 1998; 79(Pt 9): 2221-2229.
50. Mackay IM, Bialasiewicz S, Jacob KC, et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis 2006; 193(12): 1630-1633.
51. Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol 2004; 72(2): 304-306.
52. Leung J, Esper F, Weibel C, Kahn JS. Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J Clin Microbiol 2005; 43(3): 1213-1219.
53. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009; 123(2): 398-403.
54. de Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 1993; 122(5 Pt 1): 787-791.
55. Boivin G, De Serres G, Cote S, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003; 9(6): 634-640.
56. Caracciolo S, Minini C, Colombrita D, et al. Human metapneumovirus infection in young children hospitalized with acute respiratory tract disease: virologic and clinical features. Pediatr Infect Dis J 2008; 27(5): 406-412.
57. Marguet C, Lubrano M, Gueudin M, et al. In very young infants severity of acute bronchiolitis depends on carried viruses. PLoS One 2009; 4(2): e4596.
58. Freymouth F, Vabret A, Legrand L, et al. Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr Infect Dis J 2003; 22(1): 92-94.
59. Mullins JA, Erdman DD, Weinberg GA, et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004; 10(4): 700-705.
60. van den Hoogen BG, van Doornum GJ, Fockens JC, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 2003; 188(10): 1571-1577.
61. Bosis S, Esposito S, Niesters HG, Crovari P, Osterhaus AD, Principi N. Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005; 75(1): 101-104.
62. Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006; 24(1): 102-108.
63. Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med 2008; 168(22): 2489-2496.
64. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352(17): 1749-1759.
65. Hamelin ME, Cote S, Laforge J, et al. Human metapneumovirus infection in adults with communityacquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41(4): 498-502.
66. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007; 25(5): 846-855.
67. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289(2): 179-186.
68. Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981; 99(1): 100-103.
69. Muller A, Tillmann RL, Simon A, Schildgen O. Stability of human metapneumovirus and human coronavirus NL63 on medical instruments and in the patient environment. J Hosp Infect 2008; 69(4): 406-408.
70. von Linstow ML, Eugen-Olsen J, Koch A, Winther TN, Westh H, Hogh B. Excretion patterns of human metapneumovirus and respiratory syncytial virus among young children. Eur J Med Res 2006; 11(8): 329-335.
71. Abed Y, Boivin G. Human metapneumovirus infection in immunocompromised child. Emerg Infect Dis 2008; 14(5): 854-856.
72. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 2008; 143(4): 455-467.
73. Kim S, Sung H, Im HJ, Hong SJ, Kim MN. Molecular epidemiological investigation of a nosocomial outbreak of human metapneumovirus infection in a pediatric hemato-oncology patient population. J Clin Microbiol 2009; 47(4): 1221-1224.
74. Ebihara T, Endo R, Kikuta H, et al. Human metapneumovirus infection in Japanese children. J Clin Microbiol 2004; 42(1): 126-132.
75. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004; 189(8): 1388-1396.
76. von Linstow ML, Hogh M, Nordbo SA, Eugen-Olsen J, Koch A, Hogh B. A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr 2008; 167(10): 1125-1133.
77. Wolf DG, Greenberg D, Kalkstein D, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J 2006; 25(4): 320-324.
78. Madhi SA, Ludewick H, Abed Y, Klugman KP, Boivin G. Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants. Clin Infect Dis 2003; 37(12): 1705-1710.
79. Jartti T, van den Hoogen B, Garofalo RP, Osterhaus AD, Ruuskanen O. Metapneumovirus and acute wheezing in children. Lancet 2002; 360(9343): 1393-1394.
80. Heikkinen T, Osterback R, Peltola V, Jartti T, Vainionpaa R. Human metapneumovirus infections in children. Emerg Infect Dis 2008; 14(1): 101-106.
81. von Linstow ML, Larsen HH, Eugen-Olsen J, et al. Human metapneumovirus and respiratory syncytial virus in hospitalized danish children with acute respiratory tract infection. Scand J Infect Dis 2004; 36(8): 578-584.
82. Viazov S, Ratjen F, Scheidhauer R, Fiedler M, Roggendorf M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol 2003; 41(7): 3043-3045.
83. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol 2006; 35(1): 46-50.
84. Williams JV, Tollefson SJ, Nair S, Chonmaitree T. Association of human metapneumovirus with acute otitis media. Int J Pediatr Otorhinolaryngol 2006; 70(7): 1189-1193.
85. Choi EH, Lee HJ, Kim SJ, et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children 2000-2005. Clin Infect Dis 2006; 43(5): 585-592.
86. Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr 1988; 113(2): 266-271.
87. Kukavica-Ibrulj I, Hamelin ME, Prince GA, et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol 2009; 83(3): 1341-1349.
88. Williams JV, Crowe JE Jr, Enriquez R, et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005; 192(7): 1149-1153.
89. Mohapatra SS, Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev 2008; 21(3): 495-504.
90. Stensballe LG, Simonsen JB, Thomsen SF, et al. The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol 2009; 123(1): 131-137.
91. Thomsen SF, Stensballe LG, Skytthe A, Kyvik KO, Backer V, Bisgaard H. Increased concordance of severe respiratory syncytial virus infection in identical twins. Pediatrics 2008; 121(3): 493-496.
92. Thomsen SF, van der Sluis S, Stensballe LG, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. Am J Respir Crit Care Med 2009; 179(12): 1091-1097.
93. Hamelin ME, Prince GA, Gomez AM, Kinkead R, Boivin G. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. J Infect Dis 2006; 193(12): 1634-1642.
94. Schildgen O, Glatzel T, Geikowski T, et al. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis 2005; 11(3): 467-470.
95. Maggi F, Pifferi M, Vatteroni M, et al. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs frominfants in Italy. J Clin Microbiol 2003; 41(7): 2987-2991.
96. Arnold JC, Singh KK, Milder E, et al. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J 2009; 28(12): 1057-1060.
97. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with communityacquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134(6): 1141-1148.
98. De Serres G, Lampron N, La Forge J, et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46(2): 129-133.
99. Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007; 44(9): 1152-1158.
100. Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192(6): 1061-1065.
101. Larcher C, Geltner C, Fischer H, Nachbaur D, Muller LC, Huemer HP. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant 2005; 24(11): 1891-1901.
102. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144(5): 344-349.
103. Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178(8): 876-881.
104. Madhi SA, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Klugman KP. Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J 2007; 26(8): 693-699.
105. Madhi SA, Kuwanda L, Cutland C, Klugman KP. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol 2006; 36(3): 215-221.
106. Debiaggi M, Canducci F, Sampaolo M, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 2006; 194(4): 474-478.
107. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143(5 Suppl): S112-117.
108. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126(2): 212-219.
109. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94(2): 99-103.
110. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birthcohort study. Pediatrics 2007; 120(4): e1076-e1081.
111. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999; 18(10): 866-869.
112. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009; 94(10): 785-789.
113. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82(5): 2040-2055.
114. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23(9): 806-814.
115. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Differences in clinical severity between genotype A and genotype B human metapneumovirus infection in children. Clin Infect Dis 2006; 42(12): e111-e113.
116. Chung JY, Han TH, Kim SW, Hwang ES. Genotype variability of human metapneumovirus, South Korea. J Med Virol 2008; 80(5): 902-905.
117. Manoha C, Espinosa S, Aho SL, Huet F, Pothier P. Epidemiological and clinical features of hMPV, RSV and RVs infections in young children. J Clin Virol 2007; 38(3): 221-226.
118. Agapov E, Sumino KC, Gaudreault-Keener M, Storch GA, Holtzman MJ. Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness. J Infect Dis 2006; 193(3): 396-403.
119. Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006; 193(1): 54-58.
120. Stempel HE, Martin ET, Kuypers J, Englund JA, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr 2009; 98(1): 123-126.
121. Richard N, Komurian-Pradel F, Javouhey E, et al. The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J 2008; 27(3): 213-217.
122. Semple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005; 191(3): 382-386.
123. Maertzdorf J, Wang CK, Brown JB, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004; 42(3): 981-986.
124. Vinh DC, Newby D, Charest H, McDonald J. Evaluation of a commercial direct fluorescent-antibody assay for human metapneumovirus in respiratory specimens. J Clin Microbiol 2008; 46(5): 1840-1841.
125. Kukavica-Ibrulj I, Boivin G. Detection of human metapneumovirus antigens in nasopharyngeal aspirates using an enzyme immunoassay. J Clin Virol 2009; 44(1): 88-90.
126. Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by realtime polymerase chain reaction and histopathological assessment. J Infect Dis 2005; 192(6): 1052-1060.
127. Vargas SO, Kozakewich HP, Perez-Atayde AR, McAdam AJ. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr Dev Pathol 2004; 7(5): 478-486.
128. Cseke G, Maginnis MS, Cox RG, et al. Integrin alphavbeta1 promotes infection by human metapneumovirus. Proc Natl Acad Sci USA 2009; 106(5): 1566-1571.
129. Kuiken T, van den Hoogen BG, van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164(6): 1893-1900.
130. Guerrero-Plata A, Casola A, Garofalo RP. Human metapneumovirus induces a profile of lung cytokines distinct from that of respiratory syncytial virus. J Virol 2005; 79(23): 14992-14997.
131. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4): 422-434.
132. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15(1): 34-41.
133. de Swart RL, van den Hoogen BG, Kuiken T, et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 2007; 25(51): 8518-8528.
134. Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol 2007; 88(Pt 12): 3391-3400.
135. Tang RS, Mahmood K, Macphail M, et al. A hostrange restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 2005; 23(14): 1657-1667.
136. Pham QN, Biacchesi S, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 2005; 79(24): 15114-15122.
137. Herfst S, Schrauwen EJ, de Graaf M, et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008; 26(33): 4224-4230.
138. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102(3): 531-537.
139. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143(4): 532-540.
140. Committee On Infectious Diseases. Policy statement-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124(6): 1694-1701.
141. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368(3): 652-665.
142. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60(1): 51-59.
143. Hamelin ME, Couture C, Sackett M, et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther 2008; 13(1): 39-46.
144. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006; 50(2): 774-777.
145. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007; (1): CD000181.
146. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26(8): 862-864.
147. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Anti-microb Agents Chemother 2008; 52(1): 279-287.
148. Deffrasnes C, Cavanagh MH, Goyette N, et al. Inhibition of humanmetapneumovirus replication by small interfering RNA. Antivir Ther 2008; 13(6): 821-832.
149. Alvarez R, Elbashir S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53(9): 3952-3962.
150. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77(3): 225-231.